Incidence, molecular characteristics, and imaging features of “clinically-defined pseudoprogression” in newly diagnosed glioblastoma treated with chemoradiation - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Neuro-Oncology Année : 2022

Incidence, molecular characteristics, and imaging features of “clinically-defined pseudoprogression” in newly diagnosed glioblastoma treated with chemoradiation

Akifumi Hagiwara
  • Fonction : Auteur
Jacob Schlossman
  • Fonction : Auteur
Soroush Shabani
  • Fonction : Auteur
Catalina Raymond
  • Fonction : Auteur
Hiroyuki Tatekawa
  • Fonction : Auteur
Lauren Abrey
  • Fonction : Auteur
Josep Garcia
  • Fonction : Auteur
Frank Saran
  • Fonction : Auteur
Ryo Nishikawa
  • Fonction : Auteur
Roger Henriksson
  • Fonction : Auteur
Warren Mason
  • Fonction : Auteur
Wolfgang Wick
  • Fonction : Auteur
Timothy Cloughesy
  • Fonction : Auteur
Benjamin Ellingson
  • Fonction : Auteur

Résumé

Recurrent or high-grade meningiomas are an unmet medical need. Recently, we demonstrated that targeting mTOR by everolimus was relevant both in vitro and in humans. However, everolimus induces an AKT activation that may impact the anti-proliferative effect of the drug. Moreover, the MAP kinase pathway was shown to be involved in meningioma tumorigenesis. We therefore targeted both the Pi3k-AKT-mTOR and MAP kinase pathways by using combinations of the Pi3k inhibitor alpelisib and the MEK inhibitor trametinib. Our study was performed in vitro on the human meningioma cell lines and on a large series of primary cultures providing from 63 freshly operated meningiomas including 35 WHO grade 1, 23 grade 2, and five grade 3, half of which presented a NF2 genomic alteration. Alpelisib induced a higher inhibitory effect on cell viability and proliferation than everolimus in all cell lines and 32 randomly selected tumors no matter the genomic status, the histological subtype or grade. Trametinib also strongly inhibited cell proliferation and induced AKT activation. Combined treatment with alpelisib plus trametinib reversed the AKT activation induced by trametinib and induced an additive inhibitory effect irrespective of the cell lines or tumor features. Co-targeting pathways seems promising and may be considered particularly for aggressive meningioma.
Fichier non déposé

Dates et versions

hal-03976635 , version 1 (07-02-2023)

Identifiants

Citer

Akifumi Hagiwara, Jacob Schlossman, Soroush Shabani, Catalina Raymond, Hiroyuki Tatekawa, et al.. Incidence, molecular characteristics, and imaging features of “clinically-defined pseudoprogression” in newly diagnosed glioblastoma treated with chemoradiation. Journal of Neuro-Oncology, 2022, 159 (3), pp.509-518. ⟨10.1007/s11060-022-04088-3⟩. ⟨hal-03976635⟩
9 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More